Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: Eli Lilly 22.974, Structure Therapeutics 0.
Eli Lilly vs Structure Therapeutics: Revenue Comparison
Eli Lilly (LLY) and Structure Therapeutics (GPCR) are peers in GLP-1. Eli Lilly reported revenue of $23.0B as of Q2 2026, compared with $0 for Structure Therapeutics. Eli Lilly leads on revenue.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Eli Lilly, Structure Therapeutics.| Metric | Eli Lilly | Structure Therapeutics |
|---|---|---|
| Market Cap | - | - |
| Revenue | $22.97B | $0 |
| Cost of Revenue | $3.27B | $0 |
| Gross Profit | $19.71B | $0 |
| Operating Income | $8.98B | $-119.00M |
| Net Income | $7.09B | $-106.00M |
| R&D Expense | $3.82B | $100.00M |
| Earnings Per Share | $7.94 | -$1.47 |
| Gross Margin | 85.8% | - |
| Operating Margin | 39.1% | - |
| Net Profit Margin | 30.9% | - |
| Free Cash Flow | $7.76B | $-120.00M |
| Cumulative Free Cash Flow | $109.66B | $-589.00M |
| Operating Cash Flow | $10.69B | $-120.00M |
| Cash & Equivalents | $8.89B | $273.00M |